Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 7.01, 9.01 · 8-K

Aspira Women's Health Inc.

AWHLOTCEQUITYCurrent

Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 29, 2025, Aspira Women’s Health Inc. (the “Company”) published an investor presentation on its website. A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report filing on Form 8-K. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No.…

Filed Dec 31, 2025Accepted Dec 31, 2025, 7:00 AM ESTCIK 926617Accession 0000926617-25-000014
Share

Company context

We are dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer.

Current securities

Recent company filings

  1. 10-Q filingAug 14, 2026
  2. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementJul 15, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJul 7, 2026
  4. D filingJun 22, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJun 22, 2026

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 29, 2025, Aspira Women’s Health Inc. (the “Company”) published an investor presentation on its website. A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report filing on Form 8-K. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description ───────────────────────────────────────────────────────────────────────────────────────────────── 99.1 Slide Deck Published by Aspira Women’s Health On December 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Filed exhibits (1)
EX-99.1 (by filename) awhl-20251229xex99d1.htm

EX-99.1 2 awhl-20251229xex99d1.htm EX-99.1 Exhibit 99.1 Investor Presentation OTCQX: AWHL Forward -looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts contained in this presentation, including statements regarding Aspira Women’s Health, Inc.’s (the “Company’s” or Aspira”) strategy, future, operations, future financial position, projected costs, prospects, plans and objectives of management are, forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of forward-looking statements include but are not limited to our projections or expectations regarding our future test volumes, revenue, average unit price, cost of revenue, operating expenses, research and development expenses, gross profit margin, cash fl…

Open exhibit ↗